In the early hours of November 1, Lupin witnessed a 0.6 percent gain in its shares, reaching Rs 1,135.85, following the receipt of a favorable Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Mandideep Unit-2 manufacturing facility.
The EIR, issued after the facility’s inspection from August 7 to 11, was closed with a No Action Indicated (NAI) classification, signifying a satisfactory inspection status.
This development was met with enthusiasm within the company. Nilesh Gupta, Managing Director of Lupin, expressed satisfaction, stating, “We are pleased to receive the EIR with a satisfactory inspection status from the USFDA for the recent inspection of our Mandideep Unit-2 facility. This accomplishment is in line with our continued focus and commitment to becoming best-in-class in quality and compliance, and enables us to continue delivering quality affordable healthcare solutions globally.”
Following this positive news, Lupin’s shares continued to trade around 1 percent higher at ₹1,139.25 (at the time of reporting), reflecting investor confidence in the company’s commitment to maintaining high-quality standards and compliance, thereby ensuring the continued delivery of affordable healthcare solutions worldwide.